Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SRUGK
ADC Name
c208F2-E-13
Synonyms
c208F2 E-13
   Click to Show/Hide
Organization
Pierre Fabre SA.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
c208F2
  Antibody Info 
Antigen Name
Insulin-like growth factor 1 receptor (IGF1R)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
c208F2-E-13 linker
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 100
%
CVCL_0031
Invasive breast carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 62) Positive IGF1R expression (IGF1R+++/++)
Method Description
Twenty days after MCF-7 cell implantation, when tumors reached an average size of 120-150 mm3, the animals were divided into groups of 5 mice according to tumor size and aspect. All compounds were injected intraperitoncally (i.p.). In this example, the anti-tumor activity of ADCs at about DAR 4 was evaluated after 2 injections of a 7 mg/kg dose at day 20 and day 27.

   Click to Show/Hide
In Vivo Model MCF-7 CDX model
In Vitro Model Invasive breast carcinoma MCF-7 cells CVCL_0031
References
Ref 1 Antibody-drug-conjugate and its use for the treatment of cancer.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.